Eitan Medical Announces Updated Distribution Arrangement

Eitan Medical announced today that all current Sapphire™ Infusion System customers of ICU Medical in France, UK and the US will be serviced by Eitan Medical, the manufacturer of the Sapphire™ Infusion System.

Eitan Medical will now become the exclusive supplier and service provider for its own Sapphire™ Infusion System, including the provision of administration sets, accessories, spare and technical parts and repair and preventative maintenance services.

Eitan Medical has further agreed to be a distributor for administration sets manufactured by ICU Medical for the Sapphire™ Infusion System, further bolstering Eitan Medical’s current administration set supply around the world.

“This transition marks the completion of a successful and beneficial partnership between Eitan Medical and ICU Medical. We are appreciative and thankful to Dan Woolson and the entire ICU Medical team for serving as a valuable strategic partner to Eitan Medical, and for working collaboratively to provide advanced infusion therapy solutions these past few years,” said Igal Shany, CEO of Eitan Medical. “Eitan Medical strives to enhance its commitment to patient care, comfort and safety through innovation and exceptional customer experience. We continue to illustrate our patient-centricity through continued development of our flagship Sapphire™ infusion pump, a proven and well-known solution within the healthcare ecosystem, capable of answering the evolving needs of patients in need via intuitive and patient-minded performance.”

“We look forward to the successful transition of the business back to Eitan Medical and ICU Medical’s ability to focus on our Best in KLAS Plum™ platform and ICU Medical MedNet™ software to improve the safety, efficiency, and operating effectiveness of our customers’ IV therapy practices.” said Dan Woolson, Corporate Vice President and GM of ICU Medical.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”